Drugs / Anetumab Ravtansine
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT03816358 | Dec 2019 → Jan 2027 expected | pancreatic adenocarcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03455556 | Aug 2018 → Sep 2019 | non-small cell lung carcinoma | Mayo Clinic | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03102320 | May 2017 → Sep 2020 | neoplasm | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02824042 | Sep 2016 → Jun 2018 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02751918 | Jun 2016 → Aug 2019 | ovarian cancer | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02696642 | Apr 2016 → Jul 2018 | neoplasm | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02639091 | Feb 2016 → May 2018 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02485119 | Aug 2015 → Apr 2017 | neoplasm | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01439152 | Sep 2011 → Dec 2016 | — | Bayer | Completed | No outcome recorded |
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT03126630 | Oct 2018 → May 2023 overdue | malignant pleural mesothelioma | National Cancer Institute (NCI) | Active not recruiting | Missed primary |
| Phase 25 trials · 1 missed | ||||||
| Phase 2 | NCT03926143 | Jun 2019 → May 2022 | cancer | Bayer | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT03587311 | Oct 2018 → Oct 2026 expected | fallopian tube endometrioid adenocarcinoma, fallopian tube serous adenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian serous adenocarcinoma +1 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03023722 | May 2017 → Aug 2019 | malignant pancreatic neoplasm | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT02839681 | Jul 2016 → Jun 2018 | lung neoplasm | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02610140 | Dec 2015 → May 2017 | mesothelioma | Bayer | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-07-21 | Bayer | Results Phase II Trial of Investigational Anetumab Ravtansine Does Not Meet Primary Endpoint in Second-Line Mesothelioma bayer.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-07-21 | Bayer | Phase II Trial of Investigational Anetumab Ravtansine Does Not Meet Primary Endpoint in Second-Line Mesothelioma bayer.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anetumab ravtansine | “Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors” NCT02639091 ↗12“BAY94-9343 (Anetumab ravtansine) will be administered as specified in the parent studies” NCT03926143 ↗ |
| Known as | anetumab | “To assess the preliminary anti-tumor activity of anetumab ravtansine (anetumab) in combination with nivolumab, nivolumab and ipilimumab, nivolumab and gemcitabine hydrochloride...” NCT03816358 ↗1“Anetumab ravtansine is a monoclonal antibody, called anetumab, linked to a chemotherapy drug, called ravtansine.” NCT03126630 ↗ |
| Known as | Anetumab ravtansina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109629 ↗ |
| Known as | BAY94-9343 | “Cohort 1: 4.5 mg/kg of BAY 94-9343 at Q3W dose regimen. Cohort 2: 6.5 mg/kg of BAY 94-9343 at Q3W dose regimen.” NCT02485119 ↗10“intravenous anetumab ravtansine (BAY 94-9343), an anti-mesothelin antibody drug conjugate” NCT03023722 ↗ “anetumab ravtansine (BAY 94-9343) will be administered by 1-hour IV infusion” NCT02639091 ↗ “Intravenous Anetumab ravtansine (BAY 94-9343) or Vinorelbine” NCT02610140 ↗ “Anetumab ravtansine (BAY94-9343)” NCT02696642 ↗ “Anetumab ravtansine (BAY94-9343)” NCT03102320 ↗ “Anetumab ravtansine (BAY94-9343)” NCT02824042 ↗ “Anetumab ravtansine (BAY94-9343)” NCT02751918 ↗ |
| Action | Deplete | “It kills cancer cells that carry mesothelin.” NCT02839681 ↗ |
| Modality | Monoclonal antibody | “fully human anti-mesothelin monoclonal antibody conjugated to cytotoxic maytansinoid tubulin inhibitor DM4” PMID 36564099 ↗ Apr 2023 |
| Route | Intravenous | “BAY94-9343 was administered intravenously in this study.” NCT01439152 ↗ |
| Target | MSLN | “Anti-mesothelin antibody” NCT03926143 ↗ |